Name: Pentosidine (Advanced Glycation End Product)
Price: 1095.00 USD

Overview
- Protein G affinity purified antibody from ascites in stabilized buffer, containing 50% Block Ace? (Casein-containing solution, Dainippon Co.) and 0.1% ProClin? (Rohm & Haas) as a preservative
  
  Please contact us at for specific academic pricing.
  
  Background
  
  This antibody is suitable for the detection of bound and free pentosidine in tissues and tissue extracts. Long-term incubation of proteins with glucose leads, through Schiff's base and Amadori rearrangement products, to the formation of advanced glycation end products (AGE) which are characterized by fluorescence, brown color and inter- and intra-molecular cross-linking. Recent immunological studies using anti-AGE antibodies demonstrated the presence of AGE in (i) human lens, (ii) renal proximal tubules in patients with diabetic nephropathy and chronic renal failure, (iii) atherosclerotic lesions of arterial walls, (iv) ß2-microglobulin of carpal tunnel amyloid fibril deposits in patients with hemodialysis-related amyloidosis and (v) brain tissues of patients with Alzheimer’s disease. Pentosidine is one of the Maillard products, which were detected by Sell and Monnier (1989). Pentosidines have been shown to cross-link Arginine and Lysine residues. They were found in ß2-microglobulin of patients suffering from hemodialysis-related amyloidosis (Miyata et al., 1996). Reacts with pentosidine-HSA and free pentosidine in competitive ELISA.
Properties
- Host
  
  mouse
  
  Isotype
  
  IgG1
  
  Clone
  
  PEN-12
  
  Immunogen
  
  Pentosidine-HSA
  
  Purification
  
  protein G affinity purified antibody from ascites in stabilized buffer, containing 50% Block Ace? (Casein-containing solution, Dainippon Co.) and 0.1% ProClin? (Rohm & Haas) as a preservative
  
  Storage
  
  -20°C
  
  Concentration
  
  0.25 mg/ml
  
  * This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.

Applications

Application

IHC; ELISA

Application	Dilutions
ELISA	0.1-0.5 µg/ml

Reference
- 1. Horiuchi S., Araki N., and Morino Y. (1991) Immunological approach to characterize advanced glycation end products of the Maillard reaction: Evidence for the presence of a common stucture. J. Biol. Chem. 266; 7329-7332.
  2. Sell D.R. and Monnier V.M.(1989) : Structure Elucidation of a Senescence Cross-link from Human Extracellular Matrix. Implication of pentoses in aging process. J.Biol.Chem.264 : 21597-21602
  3. Miyata T, Taneda S., Kawai R., Ueda Y., Horiuchi S., Hara M., Maeda K., and Monnier V.M. (1996) : Identification of pentosidine as a native structure for advanced glycation end products in ?2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis. Proc.Natl.Acad.Sci.USA 93 : 2353-2358

Datasheet

Pentosidine (Advanced Glycation End Product)

Pentosidine (Advanced Glycation End Product)

Background

We Also Recommend

anti-AAV VP1 mouse monoclonal, A1, lyophilized, purified

anti-AAV VP1/VP2 mouse monoclonal, A69, lyophilized, purified

Anti-AAV VP1/VP2/VP3 mouse monoclonal, B1, AFDyeTM 488 Conjugate